Business
Medicenna Announces Intention to File Final Short Form Prospectus
Medicenna Announces Intention to File Final Short Form Prospectus Canada NewsWire ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Intention to File Final Short Form Prospectus\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, March 12, 2020\n\n\n\n/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./\n TORONTO and HOUSTON, March 12, 2020 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA), a clinical stage immuno-oncology company, announces that it intends to file a (final) short form prospectus (the \"Prospectus\") in each of the provinces of British Columbia, Alberta and Ontario, in connection with the marketed offering (the \"Offering\") of common shares of the Company (\"Offered Shares\"). The Company also announces that it intends to refile on SEDAR, under the Company's profile, license agreements entered into as of August 21, 2015 with Leland Stanford Junior University with respect to the in-licensing of IL-2, IL-4 and IL-13 tunable cytokines, called \"Superkines\" (collectively, the \"Stanford License Agreements\"), license agreements entered into as of September 26, 2013 with the National Institutes of Health covering composition, methods of use, combination therapy and delivery of MDNA55, as amended (the \"NIH License Agreements\"), as well as the cancer research grant contract entered into as of March 1, 2015 with the Cancer Prevention and Research Institute of Texas (the \"CPRIT Grant Contract\"), as further discussed below.\nDescription of the Offering\nPursuant to the Offering, the Company intends to issue up to 11,290,323 Offered Shares at a price of CDN$3.10 per Offered Share for gross proceeds of up to approximately CDN$35 million. The Offering is undertaken on a best efforts basis pursuant to the terms and conditions of an agency agreement (the \"Agency Agreement\") entered into among Bloom Burton Securities Inc., Mackie Research Capital Corporation, Haywood Securities Inc. (collectively, the \"Agents\") and the Company. In connection with the Offering, the Agents will be ...